# Study With Oral Ferric Maltol for the Treatment of Iron Deficiency Anemia in Subjects With Chronic Kidney Disease

> **NCT02968368** · PHASE3 · COMPLETED · sponsor: **Shield Therapeutics** · enrollment: 167 (actual)

## Conditions studied

- Renal Insufficiency, Chronic
- Iron-Deficiency Anemia

## Interventions

- **DRUG:** Ferric maltol
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02968368
- **Lead sponsor:** Shield Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12-01
- **Primary completion:** 2018-01-18
- **Final completion:** 2018-10-10
- **Target enrollment:** 167 (ACTUAL)
- **Last updated:** 2020-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02968368

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02968368, "Study With Oral Ferric Maltol for the Treatment of Iron Deficiency Anemia in Subjects With Chronic Kidney Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02968368. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*